Top Institutions in Ophthalmology - Ocular Oncology and Retina
Leading institutions combine clinical ophthalmology, ocular oncology, and advanced retinal imaging with translational research in tumor genetics and radiation therapy optimization to develop and evaluate novel approaches to reduce radiation retinopathy incidence and severity.
-
#1
University of California, Irvine - Gavin Herbert Eye Institute
Irvine, CA
Home to Dr. Kapil Mishra, a leading expert in radiation retinopathy and ocular oncology, the institute integrates clinical care with research on radiation dose optimization and genetic tumor profiling to reduce vision loss after uveal melanoma treatment.
Key Differentiators
- Ophthalmology
- Ocular Oncology
- Retina
-
#2
Wills Eye Hospital - Thomas Jefferson University
Philadelphia, PA
A premier center for retinal diseases and ocular oncology, Wills Eye has extensive experience in managing radiation retinopathy and pioneering anti-VEGF therapies and laser treatments to mitigate vision loss.
Key Differentiators
- Ophthalmology
- Retina
- Ocular Oncology
-
#3
Bascom Palmer Eye Institute - University of Miami
Miami, FL
Recognized globally for ocular oncology and retinal disease research, Bascom Palmer leads clinical trials on novel systemic therapies and radiation dose modulation to prevent radiation retinopathy.
Key Differentiators
- Ophthalmology
- Retina
- Ocular Oncology
-
#4
Memorial Sloan Kettering Cancer Center
New York, NY
A leader in cancer treatment and research, MSKCC advances understanding of tumor genetics and systemic therapies to reduce radiation complications in ocular melanoma patients.
Key Differentiators
- Ocular Oncology
- Radiation Oncology
- Medical Oncology
-
#5
Massachusetts Eye and Ear Infirmary - Harvard Medical School
Boston, MA
Known for cutting-edge retinal research and ocular oncology, this institution contributes to advancements in imaging, radiation delivery techniques, and novel therapeutics to mitigate radiation retinopathy.
Key Differentiators
- Ophthalmology
- Retina
- Ocular Oncology
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







